Passage Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
Passage Bio, Inc. is a Delaware biotechnology company listed on Nasdaq under the symbol PASG. The March 4, 2024 Form 8-K reports financial results for the year ended December 31, 2023, announces the appointment of a permanent Chief Financial Officer, and provides an updated corporate presentation.
Financial and Operating Metrics
The filing references a press release containing the Company’s 2023 financial results, but the provided filing text does not include the underlying revenue, net loss, cash flow, cash and investments, debt, liquidity, runway, margins, or other financial figures. No clear values for these metrics are available in the source text.
Material Changes
- Kathleen Borthwick was appointed Chief Financial Officer effective March 1, 2024.
- Ms. Borthwick continues to serve as Principal Financial Officer and Principal Accounting Officer.
- She previously served as Interim CFO from July 2023 through February 2024 and held finance leadership roles at Passage Bio since November 2021.
- The Company updated its corporate presentation on March 4, 2024.
Compensation and Employment Terms
- Annual base salary: $422,240.
- Target cash bonus eligibility: up to 40% of annual base salary, subject to performance criteria.
- Equity award: option to purchase 227,000 shares of common stock at an exercise price equal to the closing market price on the grant date.
- The option vests monthly over 48 months, beginning one month after the effective date, subject to continued service.
- Specified termination or change-in-control events may trigger salary continuation, COBRA-related payments, a target bonus payment, and accelerated vesting of equity awards.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not state financial guidance, cash runway, clinical or operational outlook, or specific risk factors. Investors should review Exhibit 99.1, the referenced financial-results press release, and Exhibit 99.2, the updated corporate presentation, for management commentary and forward-looking information.
The CFO appointment and related employment, severance, and change-in-control provisions represent the principal unusual items disclosed in this Form 8-K.
Important Facts to Verify
- Verify 2023 revenue, operating expenses, net loss, loss per share, cash position, cash used in operations, and expected cash runway in Exhibit 99.1.
- Review any updated clinical-development plans, program priorities, financing needs, and milestones in the corporate presentation.
- Assess the potential dilution from the 227,000-share CFO option and any other equity awards.
- Review the terms and potential cost of the disclosed severance and change-in-control provisions.
- Confirm that the financial-results press release and corporate presentation are furnished rather than filed for purposes of Exchange Act Section 18 liability, as stated in the Form 8-K.